Of these, interleukin-6 receptor inhibitors, used only in RA, pose a higher risk of serious infection than tumor necrosis factor inhibitors (64), commonly used throughout all IMIDs (63, 65–67). Here, IL6R is linked to rheumatoid arthritis.